Taken together, our data suggest that the increased levels of tenascin C in atrophic patients with COPD would in turn enhance the activation of EGF, possibly leading to reduced type I fibre distribution post-PR (figure 1), and commensurate increase in type II fibre distribution [1]. This evidence concerns the gene TNC and chronic obstructive pulmonary disease.